Synonyms: Activin A, INHBA
Garetosmab (Anti-INHBA / Activin A) is a fully human IgG4 monoclonal antibody that specifically inhibits activin A. Garetosmab can be used for fibrodysplasia ossificans progressiva (FOP) research. MW: 145.5 kD.
Shimon Sakaguchi
Nature Communications 2025,16, Article number:1325
David Baker
Dev Cell 2023, 58(20):2163-2180.e9.
David Julius
Cell 2017, 185-198.e16
Michael Houghton
Cell Chem Biol, 2020, 27(7):780-792.e5
Charles M. Rice
Cell 2018, 172(3):423-438.e25
| Featured Inhibitors | Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933 |
|---|
| Name | Citation | ALK1 | ALK2 | ALK3 | ALK4 | TGFβRI/ALK5 | ALK6 | TGFβRII | TGF-β | Smad3 | ALK7 | Others |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SB431542 | 826 | |||||||||||
| LDN-193189 | 278 | |||||||||||
| Galunisertib (LY2157299) | 193 | |||||||||||
| LY2109761 | 138 | |||||||||||
| SB-525334 | 120 | |||||||||||
| SB505124 | 37 | |||||||||||
| GW788388 | 26 | |||||||||||
| LY364947 | 49 | RIPK2,CK1δ,MLK-7K | ||||||||||
| RepSox (E-616452) | 86 | |||||||||||
| LDN-193189 Dihydrochloride | 108 | |||||||||||
| K02288 | 25 | |||||||||||
| TGFβRI-IN-3 | 2 | |||||||||||
| R-268712 | 1 | |||||||||||
| BIBF-0775 | 0 | |||||||||||
| TP0427736 HCl | 6 | |||||||||||
| A-83-01 | 75 | |||||||||||
| LDN-214117 | 4 | |||||||||||
| SD-208 | 23 | |||||||||||
| Vactosertib (TEW-7197) | 29 | |||||||||||
| ML347 | 5 | |||||||||||
| LDN-212854 | 8 | |||||||||||
| DMH1 | 63 | |||||||||||
| Dorsomorphin Dihydrochloride | 515 | AMPK | ||||||||||
| PF-06952229 | 0 | |||||||||||
| Ginsenoside Rh4 | 0 | |||||||||||
| SIS3 | 17 | |||||||||||
| AUDA | 1 | TNF-α,IL-1β,MMP-9 | ||||||||||
| PD 169316 | 2 | Activin A,Enterovirus71,p38 MAPK | ||||||||||
| TA-02 | 0 | p38 MAPK | ||||||||||
| ITD-1 | 15 | |||||||||||
| LY 3200882 | 7 | |||||||||||
| Alantolactone | 3 | STAT3 | ||||||||||
| Halofuginone | 13 | prolyl-tRNA synthetase | ||||||||||
| SIS3 Hydrochloride | 86 | |||||||||||
| Dorsomorphin (Compound C) | 478 | AMPK | ||||||||||
| Hesperetin | 4 | Histamine receptor |
| Description |
Garetosmab (Anti-INHBA / Activin A) is a fully human IgG4 monoclonal antibody that specifically inhibits activin A. Garetosmab can be used for fibrodysplasia ossificans progressiva (FOP) research. MW: 145.5 kD.
|
|---|
| CAS No. | 2097125-54-5 |
|---|---|
| Molecular Weight | 145.5 kDa |
| Isotype | Human IgG4SP |
| Source | CHO |
| Purification | AKTA |
| Sterility | 0.2 μM filtered |
| Formulation | 100 mM Pro-Ac, 20mM Arg, pH5.0 |
| Storage (From the date of receipt) |
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|---|
| NCT07559513 | NOT_YET_RECRUITING | Drug: garetosmab | Fibrodysplasia Ossificans Progressiva (FOP) | Regeneron Pharmaceuticals | 2027-02-02 | PHASE3 |
| NCT06299098 | ACTIVE_NOT_RECRUITING | Drug: Trevogrumab-Part A|Drug: Trevogrumab-Part B and Part C | Obesity | Regeneron Pharmaceuticals | 2024-03-13 | PHASE2 |
| NCT06970405 | WITHDRAWN | Drug: Garetosmab|Drug: Matching Placebo | Obesity | Regeneron Pharmaceuticals | 2025-05-29 | PHASE1 |
| NCT07253363 | ACTIVE_NOT_RECRUITING | Pulmonary Hypertension | Assistance Publique - Hôpitaux de Paris | 2024-03-01 | ||
| NCT05394116 | ACTIVE_NOT_RECRUITING | Drug: Garetosmab|Drug: Placebo | Fibrodysplasia Ossificans Progressiva | Regeneron Pharmaceuticals | 2022-11-21 | PHASE3 |
| NCT04577820 | WITHDRAWN | Drug: garetosmab | Fibrodyplasia Ossificans Progressiva (FOP); Heterotopic Ossification (HO) | Regeneron Pharmaceuticals | 2021-10-13 | PHASE3 |
(data from https://clinicaltrials.gov, updated on 2026-08-24)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.